China's export volume of API continues to decline

as a major exporter of API, China by India, Brazil, many domestic API manufacturers are forced to sacrifice export prices in exchange for salesGaE
Yesterday, reporters from the China Medical and Health Products Import and Export Chamber of Commerce (hereinafter referred to as the "Health Insurance Chamber of Commerce") was informed that in the first quarter of this year, China's bulk of raw materials exports are still weak, exports of only 2.07 billion U.Sdollars, down 1.97% YoY, which is also since the fourth quarter of 2012, the sixth consecutive quarter of export volume declineGaE
The Medical Insurance Chamber of Commerce said that since the fourth quarter of 2012, China's single-quarter exports of bulk API continued to show negative growth year-on-year, and the magnitude continued to expand, in the third quarter of 2013 year-on-year decline of 9.52 percent, the largest decline in historyGaE
"The existing advantages of China's low-cost labor has been lost, coupled with the devaluation of the currencies of India, Brazil and Southeast Asian countries to further reduce the international competitiveness of China's pharmaceutical products, some international orders to lower labor costs of ASEAN, India and other countries or regions, so that china's RAW materials export enterprises have been relying on low-cost food, " said the relevant person in charge of the Medical Insurance Chamber of Commerce, "At present, the enterprise simply by sacrificing export prices in exchange for export volume recovery practices can be sustained is still unknown." "
GaEon the other hand, the domestic regulatory system is becoming more stringent, accelerating the reshuffleIn recent years, many pharmaceutical companies have expanded their production capacity, shifting production lines to the less labor-efficient western regions, boosting local GDP and adding jobs, and customs data show rapid growth in pharmaceutical exports in the western region, said one pharmaceutical company official, who did not want to be namedHowever, environmental protection has been a problem that plagues the development of our country's enterprisesThis year, the country's widespread haze is prevalent, it can be expected that this year's policy will increase the supervision of enterprises sewage inspection and rectification effortsThe Health Insurance Chamber of Commerce predicts that the global economy will be divided this year, with the economy generally improving in Europe and the US, while most emerging economies are underperforming The devaluation of the currencies of major competitors such as India weakens the competitiveness of our pharmaceutical products, and the international regulatory environment becomes more severe, the development of China's pharmaceutical foreign trade is facing a severe test However, with the rapid pace of transformation and upgrading of China's pharmaceutical enterprises, China's pharmaceutical foreign trade is still an opportunity
GaE as a major exporter of raw materials, China by India, Brazil, many domestic API manufacturers were forced to sacrifice export prices in exchange for sales GaE
　　Yesterday, reporters from the China Medical and Health Products Import and Export Chamber of Commerce (hereinafter referred to as the "Health Insurance Chamber of Commerce") was informed that in the first quarter of this year, China's bulk of raw materials exports are still weak, exports of only 2.07 billion U.S dollars, down 1.97% YoY, which is also since the fourth quarter of 2012, the sixth consecutive quarter of export volume decline GaE
　　The Medical Insurance Chamber of Commerce said that since the fourth quarter of 2012, China's single-quarter exports of bulk API continued to show negative growth year-on-year, and the magnitude continued to expand, in the third quarter of 2013 year-on-year decline of 9.52 percent, the largest decline in history GaE
　　"The existing advantages of China's low-cost labor has been lost, coupled with the devaluation of the currencies of India, Brazil and Southeast Asian countries to further reduce the international competitiveness of China's pharmaceutical products, some international orders to lower labor costs of ASEAN, India and other countries or regions, so that china's RAW materials export enterprises have been relying on low-cost food, " said the relevant person in charge of the Medical Insurance Chamber of Commerce, "At present, the enterprise simply by sacrificing export prices in exchange for export volume recovery practices can be sustained is still unknown." "
GaE on the other hand, the domestic regulatory system is becoming more stringent, accelerating the reshuffle In recent years, many pharmaceutical companies have expanded their production capacity, shifting production lines to the less labor-efficient western regions, boosting local GDP and adding jobs, and customs data show rapid growth in pharmaceutical exports in the western region, said one pharmaceutical company official, who did not want to be named However, environmental protection has been a problem that plagues the development of our country's enterprises This year, the country's widespread haze is prevalent, it can be expected that this year's policy will increase the supervision of enterprises sewage inspection and rectification efforts The Health Insurance Chamber of Commerce predicts that the global economy will be divided this year, with the economy generally improving in Europe and the US, while most emerging economies are underperforming The devaluation of the currencies of major competitors such as India weakens the competitiveness of our pharmaceutical products, and the international regulatory environment becomes more severe, the development of China's pharmaceutical foreign trade is facing a severe test However, with the rapid pace of transformation and upgrading of China's pharmaceutical enterprises, China's pharmaceutical foreign trade still exists opportunities
GaE